id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-6617-0012,FDA,FDA-2017-D-6617,"Developing Targeted Therapies in Low-Frequency Molecular Subsets of a
Disease; Guidance for Industry; Availability",Notice,Notice of Availability,2018-10-16T04:00:00Z,2018,10,2018-10-16T04:00:00Z,,2018-10-16T13:47:23Z,2018-22437,0,0,09000064837eb2a4
FDA-2017-D-6617-0011,FDA,FDA-2017-D-6617,Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease - Guidance for Industry,Other,Guidance,2018-10-15T04:00:00Z,2018,10,2018-10-15T04:00:00Z,,2024-11-07T01:27:59Z,,1,0,09000064837dc4e8
FDA-2017-D-6617-0002,FDA,FDA-2017-D-6617,Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease,Other,Guidance,2017-12-18T05:00:00Z,2017,12,2017-12-18T05:00:00Z,2018-02-17T04:59:59Z,2024-11-07T01:13:32Z,,1,0,0900006482d341b2
FDA-2017-D-6617-0001,FDA,FDA-2017-D-6617,"Developing Targeted Therapies in Low-Frequency Molecular Subsets of a
Disease; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-12-18T05:00:00Z,2017,12,2017-12-18T05:00:00Z,2018-02-17T04:59:59Z,2018-02-17T02:01:16Z,2017-27156,0,0,0900006482d3028d